Covaxin shows 50% effectiveness against symptomatic COVID-19, says study published in Lancet Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.